Another anti-hypertrophic miRNA, miR-378, controls cardiac hypertrophy in the TAC model via repression of mitogen activated protein kinase (MAPK) signaling by targeting Mapk1, insulin-like growth factor receptor 1 (Igf1r), growth factor receptor-bound protein 2 (Grb2), and kinase suppressor of ras 1 (Ksr1) [20]. The gene discussed is IGF1R; the disease is cardiac hypertrophy.